The Role of the GP in the Management of Ambulatory Heart Failure
GPsHF
1 other identifier
observational
300
1 country
1
Brief Summary
To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2021
CompletedFirst Posted
Study publicly available on registry
September 24, 2021
CompletedStudy Start
First participant enrolled
October 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2023
CompletedJune 22, 2023
June 1, 2023
11 months
May 11, 2021
June 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Quantitative analysis of verbatims after grouping
Through study completion, an average of 1 year
Study Arms (1)
Heart Failure Patients with impaired ejection fraction
Eligibility Criteria
Heart failure patients with impaired ejection fraction (LVEF \< 40%), under 85 years of age, admitted to the emergency department for cardiac decompensation and hospitalised in the aftermath of this decompensation, for whom the sum of the doses of ACE inhibitor or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient
You may qualify if:
- Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF \< 40%)
- Under 85 years of age
- Admitted to an Emergency department for cardiac decompensation
- Hospitalized following this decompensation
- Not deceased within one month of hospitalisation
- Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient\* (definition in annex)
- Who did not object within one month of being informed
You may not qualify if:
- Patient who is a minor
- Patient who does not have a general practitioner
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jean-Marc BOIVINlead
Study Sites (1)
CHRU of Nancy
Vandœuvre-lès-Nancy, 54500, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 11, 2021
First Posted
September 24, 2021
Study Start
October 1, 2022
Primary Completion
September 1, 2023
Study Completion
September 1, 2023
Last Updated
June 22, 2023
Record last verified: 2023-06